Lipoatrophy Induced by Subcutaneous Administration of Octreotide in the Treatment of Acromegaly

Abstract

Octreotide is the first somatostatin analogue to become available for clinical use in the treatment of acromegaly. To our knowledge, there are no reports describing lipoatrophy in patients treated with octreotide. Here, we report three patients who developed lipoatrophy after treatment with subcutaneous octreotide. Three patients (all women; 36, 43, and 50 years of age) with diagnosis of acromegaly due to pituitary macroadenoma who had undergone transsphenoidal surgery and radiotherapy received subcutaneos octreotide because of uncontrolled disease. The dose of octreotide was increased gradually in all patients. Lipoatrophy was noticed around the injection sites after about 6 years, 30 months, and 4 years of subcutaneous octreotide treatment in all patients. Thereafter, subcutaneous octreotide treatment was changed to intramuscular octreotide-LAR injection in all patients. In two of them, lipoatrophy around all injection sites did not regress after about 8 and 12 months of octreotide-LAR treatment, respectively. In the third patient, lipoatrophy around the injection sites regressed after 12 months of octreotide-LAR treatment. These cases highlight a potential for subcutaneous octreotide to induce lipoatrophy. The underlying mechanism is unknown but an immunological mechanism which is seen in lipoatrophy induced by insulin may be involved in the pathogenesis. Besides; simple trauma, personal susceptibility, mistakes in the administration of the drug, a problem in drug pH, or an idiosyncratic reaction of adipocytes to octreotide or additives in the drug may have caused lipoatrophy in our patients. Lipoatrophy in these cases was observed on long-term subcutaneous octreotide administration. Although intramuscular octreotide-LAR has largely replaced subcutaneous octreotide, we suggest close clinical follow-up for lipoatrophy in patients who are still on subcutaneous octreotide.

Acromegaly - lipoatrophy - octreotide - side effect - insulin

References

• 1 Ampudia-Blasco F J, Hasbum B, Carmena R. A new case of lipoatrophy with lispro insulin in insulin pump therapy. Is there any insulin preparation free of complications?.  Diabetes Care. 2003;  26 953-954
• 2 Atlan-Gepner C, Bongrand P, Farnarier C, Xerri L, Choux R, Gauthier J F, Brue T, Vague P, Grob J J, Vialettes B. Insulin-induced lipoatrophy in type 1 diabetes. A possible tumor necrosis factor-α-mediated dedifferentiation of adipocytes.  Diabetes Care. 1996;  19 1283-1285
• 3 Chantelau E, Reuter M, Schotes S, Starke A AR. A case of lipoatrophy with human insulin-therapy.  Exp Clin Endocrinol. 1993;  101 194-196
• 4 Davies P H, Stewart S E, Lancranjan I, Sheppard M C, Stewart P M. Long-term therapy with long-acting octreotide (Sandostatin-LAR®) for the management of acromegaly.  Clin Endocrinol. 1998;  48 311-316
• 5 Drago F, Rongioletti F, Battifoglio M L, Rebora A. Localised lipoatrophy after acupuncture.  Lancet. 1996;  347 1484
• 6 Garg A. Lipodystrophies.  Am J Med. 2000;  108 143-152
• 7 Griffin M E, Feder A, Tamborlane W V. Lipoatrophy associated with lispro insulin in insulin pump therapy. An old complication, a new cause?.  Diabetes Care. 2001;  24 174
• 8 Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors.  Exp Clin Endocrinol Diabetes. 1996;  104 106-110
• 9 Jaap A J, Horn H M, Tidman M J, Walker J D. Lipoatrophy with human insulin.  Diabetes Care. 1996;  19 1289-1290
• 10 Jermendy G, Nádas J, Sápi Z. “Lipoblastoma-like” lipoatrophy induced by human insulin: morphological evidence for local dedifferentiation of adipocytes?.  Diabetologia. 2000;  43 955-956
• 11 Kayikcioglu A, Mustafa A, Erk Y. Semicircular lipoatrophy after intragluteal injection of benzathine penicillin.  J Pediatr. 1996;  129 166-167
• 12 Lami M C, Hadjadj S, Guillet G. Hair loss in three patients with acromegaly treated with octreotide.  Br J Dermatol. 2003;  149 655-656
• 13 Lancranjan I, Atkinson A B. the Sandostatin®LAR® Group . Results of a European Multicentre Study with Sandostatin®LAR® in acromegalic patients.  Pituitary. 1999;  1 105-114
• 14 Logwin S, Conget I, Jansa M, Vidal M, Nicolau C, Gomis R. Human insulin-induced lipoatrophy. Successful treatment using a jet-injection device.  Diabetes Care. 1996;  19 255-256
• 15 Melmed S. Somatostatin analogues: the breadth of applications and a look into the future. Lamberts SWJ Atherosclerosis. Bristol, UK; BioScientifica Ltd 1999: 9-25
• 16 Murao S, Kyoji H, Ishida T, Takahara J. Lipoatrophy induced by recombinant human insulin injection.  Intern Med. 1998;  37 1031-1033
• 17 Newman C B, Melmed S, Snyder P J, Young W F, Boyajy L D, Levy R, Stewart W N, Klibanski A, Molitch M E, Gagel R F. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study.  J Clin Endocrinol Metab. 1995;  80 2768-2775
• 18 Priestley G C, Aldridge R D, Sime P J, Wilson D. Skin fibroblast activity in pretibial myxoedema and the effect of octreotide (Sandostatin®) in vitro.  Br J Dermatol. 1994;  131 52-56
• 19 Reeves W G, Allen B R, Tattersall R B. Insulin-induced lipoatrophy: evidence for an immune pathogenesis.  Br Med J. 1980;  280 1500-1503
• 20 van der Lely A J, de Herder W W, Lamberts S WJ. A risk-benefit assessment of octreotide in the treatment of acromegaly.  Drug Saf. 1997;  17 317-324